TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04688554

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI and DTI
Description: Neurologic imaging correlates

Intervention type: BEHAVIORAL
Intervention: Behavioral questionnaires
Description: RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam

Intervention type: BEHAVIORAL
Intervention: Behavioral questionnaires
Description: RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam

Intervention type: BEHAVIORAL
Intervention: Behavioral questionnaires
Description: RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam
Study: NCT04634227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Following 15g test dose, 75g administered 75g dose on days 1 and 2. Further doses of ascorbate will be determined by serum ascorbate levels measured by the end of the week to reach a target serum concentration between 20 -30 mM. Ascorbate doses will continue to be escalated until either the target serum concentration or maximum dose of 125 g is administered.
Study: NCT04688554

Intervention type: BEHAVIORAL
Intervention: Behavioral questionnaires
Description: RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam

Intervention type: BEHAVIORAL
Intervention: Disease-Specific Patient-Reported Outcomes
Description: Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)
Study: NCT04065347

Intervention type: DEVICE
Intervention: Digital Pill
Description: Digital Pill over encapsulating tenofovir alafenamide ART

Intervention type: DEVICE
Intervention: Digital Pill
Description: Digital Pill over encapsulating tenofovir alafenamide ART
Study: NCT02373124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion of NMDA antagonist
Description: 52 minute infusion
Study: NCT04527068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg intravenously every 3week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripleitriumab
Description: 240mg intravenously every 3week
Study: NCT04688554

Intervention type: BEHAVIORAL
Intervention: Disease-Specific Patient-Reported Outcomes
Description: Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)
Study: NCT03640663

Intervention type: OTHER
Intervention: Midwife led continuity model of care
Description: Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
Study: NCT04179578

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crura plastic
Description: Closure of hiatus with a running suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crura plastic
Description: Closure of hiatus with a running suture
Study: NCT03394404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG-I mapping and PVI
Description: ECG-I mapping and PVI
Study: NCT04176770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP Block
Description: ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
Study: NCT04406272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB11
Description: Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB11
Description: Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous solution that has no therapeutic effect, used as a control in testing investigational drug.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous solution that has no therapeutic effect, used as a control in testing investigational drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A type of antibody, Bevacizumab is intravenously administered and works by binding to and disrupting the vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulates the formation of blood vessels. By disrupting VEGF, Bevacizumab helps to prevent the growth and maintenance of tumor blood vessels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A type of antibody, Bevacizumab is intravenously administered and works by binding to and disrupting the vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulates the formation of blood vessels. By disrupting VEGF, Bevacizumab helps to prevent the growth and maintenance of tumor blood vessels.
Study: NCT03197506

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01275183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir and cisplatin
Description: Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours~Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19~Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles
Study: NCT03852329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral skull base navigation
Description: Patient preparation: The participant is prepared for the surgery according to clinical standards.~System setup: The hardware components of the investigational device are set up~Tripod fixation: The tripod with integrated registration fiducials is fixed on the participant's skull.~CBCT imaging: A CBCT image of the participant is acquired~Image processing: The CBCT data is loaded on the navigation platform. The registration fiducials are automatically detected in the image data and relevant anatomy is segmented using an otologic planning software.~Measurements: The navigation software is started, and the fiducial positions and segmentations loaded. The measurements are conducted.~Treatment: The surgery is conducted by the surgeon according to clinical standards
Study: NCT01728155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study: NCT00368940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH
Description: PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ST-CI
Description: Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
Study: NCT02699905

Intervention type: OTHER
Intervention: phlebotomy
Description: phlebotomy

Intervention type: OTHER
Intervention: phlebotomy
Description: phlebotomy
Study: NCT01786408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP20-C

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM
Study: NCT01336738

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets (n=6), 0 mg, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg PF-04991532
Description: Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 450 mg PF-04991532
Description: Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg PF-04991532
Description: Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
Study: NCT03042312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
Study: NCT01831635

Intervention type: OTHER
Intervention: Methodological pens
Description: Randomisation of branded pen, non-branded pen and no pen

Intervention type: OTHER
Intervention: Methodological pens
Description: Randomisation of branded pen, non-branded pen and no pen

Intervention type: OTHER
Intervention: Methodological pens
Description: Randomisation of branded pen, non-branded pen and no pen

Intervention type: OTHER
Intervention: Methodological compensation
Description: Randomisation of a £10 monetary reimbursement for expenses on completion of the study

Intervention type: OTHER
Intervention: Methodological compensation
Description: Randomisation of a £10 monetary reimbursement for expenses on completion of the study

Intervention type: OTHER
Intervention: Methodological compensation
Description: Randomisation of a £10 monetary reimbursement for expenses on completion of the study

Intervention type: OTHER
Intervention: Methodological trolley tokens
Description: Trolley tokens to be randomly assigned to half of cases and General Practice controls.

Intervention type: OTHER
Intervention: Methodological trolley tokens
Description: Trolley tokens to be randomly assigned to half of cases and General Practice controls.
Study: NCT00543881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (Partnership for the Heart)
Description: Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
Study: NCT03162250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSTA4637S
Description: DSTA4637S will be administered as an IV infusion at 3 dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSTA4637S
Description: DSTA4637S will be administered as an IV infusion at 3 dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSTA4637S
Description: DSTA4637S will be administered as an IV infusion at 3 dose levels.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to DSTA4637S IV infusion will be administered as specified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
Study: NCT03197506

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT02023034

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Virtual exercises
Description: The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual exercises
Description: The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
Study: NCT04499404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding related information delivered by WeChat
Description: Participants in the intervention group will be asked to follow our WeChat public account immoderately after randomization. They will receive breastfeeding related messages three times a week from WeChat, including preparation for breastfeeding after birth and the health benefits of breastfeeding, from baseline until childbirth. After childbirth, intervention group mothers will continue to receive information, which is mainly about breastfeeding, once a week for 6 months. WeChat will send push notifications to remind mothers about the importance of exclusive breastfeeding, build confidence and motivate them to continue exclusive breastfeeding.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-breastfeeding related information delivered by WeChat
Description: Participants in the control group will be asked to follow our WeChat public account immoderately after randomization. They will receive messages mainly on topics of healthy lifestyle and nutrition during pregnancy, from baseline until childbirth. After childbirth, they will continue to receive information on other topics of interest to mothers, such as immunization, safety, infant growth, and etc., until 6 months postpartum.
Study: NCT03197506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04192747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention of de novo native coronary artery lesions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention of de novo native coronary artery lesions
Study: NCT03475186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 2.5 - 5 mg oral, 1x daily for 22 weeks
Study: NCT04190745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab+Apatinib mesylate
Description: Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80mg/m2, q3w
Study: NCT02359266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Given to patients with existing vitamin D deficiency
Study: NCT00585065

Intervention type: DEVICE
Intervention: CRT device implant
Description: The purpose of this study is to collect information on patients with chronic heart failure who have already been identified by their physician as candidates for CRT. All tests, including device implantation are standard of care for patients undergoing CRT. The only test involved in this study that is not standard of care is the quality of life questionnaire. Patients who undergo CRT system implant will be followed post-implant (up to 1 week), and at one month, three months, six months and twelve months. The only test involved in this study that is not standard of care is the quality of life questionnaire.
Study: NCT02352324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid responsiveness tests
Description: After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
Study: NCT03873285

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic diagnostic by mendeliome or genome
Description: For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
Study: NCT02659865

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478 original formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478 new formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478 new formulation
Description: Administered orally
Study: NCT03919175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
Study: NCT00672477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03986944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back capsule (E2 1 mg / NETA 0.5 mg)
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 75 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet to match 75 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 200 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet to match 200 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule to match Add-back capsule
Description: For oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule to match Add-back capsule
Description: For oral administration once daily